# Glycosaminoglycan binding to soluble CX3CL1 impacts monocyte migration in vitro

**Authors:** Maria Ennemoser, Paula Peinsipp, Tihana Novak, Clara Matteini, Dorian Tauschmann, Tanja Gerlza, Andreas J. Kungl

PMC · DOI: 10.3389/fimmu.2026.1747705 · Frontiers in Immunology · 2026-02-06

## TL;DR

This study shows that glycosaminoglycans like heparan sulfate and dermatan sulfate bind to a soluble form of CX3CL1, influencing monocyte migration and receptor interactions.

## Contribution

The study reveals novel interactions between CX3CL1, glycosaminoglycans, and CX3CR1, suggesting a cooperative network in cell migration.

## Key findings

- Soluble CX3CL1 binds to heparan sulfate and dermatan sulfate with mid-nanomolar affinity.
- Monocyte migration induced by CX3CL1 is reduced when heparan sulfate is removed from the cell surface.
- CX3CR1 binds to heparan sulfate and cross-linking with CX3CL1 increases its binding affinity tenfold.

## Abstract

In addition to providing shear-resistant cell-cell adhesion in its natural membrane-bound form, the soluble variant of CX3CL1 (or fractalkine) promotes strong cell migration through signaling via its unique G-protein-coupled receptor CX3CR1 on monocytes, macrophages, T-cells, and NK-cells. To induce cell migration, most chemokines benefit from their interaction with the heterogenous group of glycosaminoglycans (GAGs), which act as coreceptors in chemotactic processes. While the interaction of many chemokines with their GAG counterparts has been investigated in detail, the potential interaction of CX3CL1 and GAGs has not yet received sufficient attention.

Here, we show that the bioactive N-terminal, soluble chemokine domain of CX3CL1 (cdCX3CL1) binds to heparan sulfate (HS) as well as to dermatan sulfate (DS or CS-B), exhibiting Kd-values in the mid nanomolar range. Moreover, the removal of monocyte-surface HS reduced cdCX3CL1-induced cell migration, thereby strongly indicating a potential biological relevance of CX3CL1 binding to GAGs. Interaction studies taking into account the extracellular receptor-peptide of CX3CR1 showed that, in addition to binding CX3CL1, CX3CR1 was found to bind to HS as well. Cross-linking cdCX3CL1 and the CX3CR1 peptide led to a ten-fold higher HS binding affinity compared to the isolated proteins.

These findings further strengthen the assumption of an extended interaction network, in which GPCR, chemokine, and GAGs affect each other simultaneously.

## Linked entities

- **Proteins:** CX3CL1 (C-X3-C motif chemokine ligand 1), CX3CR1 (C-X3-C motif chemokine receptor 1)
- **Chemicals:** heparan sulfate (PubChem CID 137699201), dermatan sulfate (PubChem CID 32756)

## Full-text entities

- **Genes:** CX3CL1 (C-X3-C motif chemokine ligand 1) [NCBI Gene 6376] {aka ABCD-3, C3Xkine, CXC3, CXC3C, NTN, NTT}, ADAM17 (ADAM metallopeptidase domain 17) [NCBI Gene 6868] {aka ADAM18, CD156B, CSVP, HYPT16, NISBD, NISBD1}, CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, HAMP (hepcidin antimicrobial peptide) [NCBI Gene 57817] {aka HEPC, HFE2B, LEAP1, PLTR}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, ADAM10 (ADAM metallopeptidase domain 10) [NCBI Gene 102] {aka AD10, AD18, CD156c, CDw156, HsT18717, MADM}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, TNC (tenascin C) [NCBI Gene 3371] {aka 150-225, DFNA56, GMEM, GP, HXB, JI}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CCL26 (C-C motif chemokine ligand 26) [NCBI Gene 10344] {aka IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1}, mucin [NCBI Gene 100508689], CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}
- **Diseases:** cardiovascular and cerebrovascular diseases (MESH:D002318), end-stage kidney disease (MESH:D007676), Rheumatoid arthritis (MESH:D001172), oncological diseases (MESH:D000072716), IPTG (MESH:C538319), liver and renal disorders (MESH:D017093), HS (MESH:D009084), lupus nephritis (MESH:D008181), endothelial impairment (MESH:D020141), diseases (MESH:D004194), glomerular inflammation (MESH:D007249), systemic lupus erythematosus (MESH:D008180), AIDS (MESH:D000163)
- **Chemicals:** saccharide (MESH:D002241), amino acids (MESH:D000596), GAG (MESH:D006025), penicillin (MESH:D010406), Chondroitin (MESH:D002807), DS (MESH:D003903), 1xPBS (-), HS (MESH:D006497), Formaldehyde (MESH:D005557), guaHCl (MESH:D019791), calcium (MESH:D002118), Chondroitin sulfate B (MESH:D003871), PBS (MESH:D007854), tryptophan (MESH:D014364), heparin (MESH:D006493), CS (MESH:D002586), CO2 (MESH:D002245), glutamine (MESH:D005973), Coomassie brilliant blue (MESH:C004692), streptomycin (MESH:D013307), polyacrylamide (MESH:C016679), polysaccharide (MESH:D011134), phosphate (MESH:D010710), salt (MESH:D012492), Chondroitin sulfate (MESH:D002809), KS (MESH:D007632), NaCl (MESH:D012965), kanamycin (MESH:D007612), glycine (MESH:D005998), Enoxaparin (MESH:D017984), HA (MESH:D006820), SP (MESH:C000604007), silver (MESH:D012834), SDS (MESH:D012967), disaccharide (MESH:D004187)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 37  C, K59A, K36, R37, K54, K54A, K59, R37A, K36A
- **Cell lines:** BL21Star(DE3) — Canis lupus familiaris (Dog), Canine mammary carcinoma, Cancer cell line (CVCL_B7H9), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920477/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920477/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920477/full.md

---
Source: https://tomesphere.com/paper/PMC12920477